Financial Data and Key Metrics Changes - In 2025, Prothena reported a net cash used in operating and investing activities of $163.7 million, which was favorable compared to the guidance range of $170 million to $178 million [37] - The net loss for 2025 was $244.1 million, aligning with the guidance range of $240 million to $248 million [37] - As of December 31, 2025, Prothena had $308.4 million in cash, cash equivalents, and restricted cash, exceeding the guidance of $298 million [38] - For 2026, the expected net cash used in operating and investing activities is projected to be between $50 million and $55 million, with an estimated net loss of $67 million to $72 million [38][39] Business Line Data and Key Metrics Changes - Prothena's clinical pipeline saw significant advancements, with two partnered programs, prasinezumab and coramitug, moving into phase III clinical trials [6][7] - The phase II TargetTau-1 clinical trial for BMS-986446 in early Alzheimer's disease was fully enrolled in 2025, with completion expected in the first half of 2027 [8] - The company introduced its CYTOPE technology, demonstrating potential for precise targeting of intracellular disease pathways [9][30] Market Data and Key Metrics Changes - The phase III PARAISO trial for prasinezumab is expected to enroll approximately 900 participants, with primary completion anticipated in 2029 [16] - The phase III CLEOPATRA trial for coramitug is set to enroll around 1,280 ATTR-CM patients, with primary completion also expected in 2029 [23] - Prothena's partnered clinical programs have the potential to deliver up to approximately $3 billion in future milestone payments, in addition to any royalties [12] Company Strategy and Development Direction - Prothena aims to capture value from clinical partnerships, with potential clinical milestone payments of up to $105 million in 2026 [10][41] - The company plans to implement a share redemption program and invest in its preclinical portfolio to support ongoing partnering efforts [10][41] - Prothena is focused on advancing its knowledge of the preclinical portfolio to explore research collaborations and licensing agreements [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust pipeline addressing significant unmet needs for millions of patients [40] - The company highlighted the importance of upcoming milestones and the potential for significant medical advances in areas with high unmet needs [46] - Management emphasized the strategic importance of the share redemption program and the potential for clinical milestone payments from partners [47][48] Other Important Information - Prothena's cash position as of year-end 2025 was $308.4 million, allowing for prudent capital utilization to support future potential economics from partner programs [11] - The company is engaged in research collaborations exploring multiple approaches for applying its CYTOPE technology [10] Q&A Session Summary Question: Key milestones for partnered program trials for PARAISO and CLEOPATRA - Management outlined that significant activities are expected in 2026 and 2027, including data from the CYTOPE activities and the phase II tau program with Bristol Myers Squibb [44][46] Question: Keeping the amyloid beta story alive against competitors - Management discussed the advantages of the PRX-012 transferrin-based approach and the potential for improved profiles compared to existing therapies [51][55] Question: Data sharing from the phase I study of PRX-019 - Management indicated that data will be shared with Bristol Myers Squibb, who holds global rights to the program, and will decide on public dissemination [62][68] Question: Data necessary for securing a partnership for the CYTOPE platform - Management highlighted the importance of robust in-vivo data demonstrating the technology's ability to target intracellular disease pathways effectively [71][75]

Summary of Larimar Therapeutics FY Conference Call Company Overview - **Company**: Larimar Therapeutics (NasdaqGM:LRMR) - **Focus**: Development of therapies for Friedreich's ataxia (FA), a rare neurodegenerative disease Industry Context - **Disease**: Friedreich's ataxia is characterized by a deficiency in frataxin, affecting approximately 5,000 patients in the U.S. and 20,000 globally. The disease typically manifests in childhood, leading to severe disability and early mortality [5][6][7]. Core Points and Arguments - **Unmet Medical Need**: Current therapies do not address the root cause of frataxin deficiency. Larimar aims to be the first disease-modifying therapy for FA [8][11]. - **Mechanism of Action**: The therapy, nomlabofusp, is designed to deliver frataxin to mitochondria, potentially restoring normal levels and halting disease progression [9][10][30]. - **Clinical Data**: - Patients with lower frataxin levels experience earlier onset and faster progression of the disease. Increasing frataxin levels to 22% can delay onset by four years and slow progression [12][13]. - Larimar has completed four studies and is currently conducting an open-label study to collect data on frataxin levels and clinical outcomes [14][28]. - The company reported an improvement of 2.25 points in the mFARS score in their patient population, compared to a worsening of 1 point in a reference population [28][29]. Regulatory Status - **Accelerated Approval**: Larimar plans to submit a Biologics License Application (BLA) in Q2 2026, targeting an early 2027 launch. The application will utilize frataxin levels as a novel surrogate endpoint [14][35]. - **Designations**: The company holds orphan drug designation, rare pediatric disease designation, and Fast Track status in the U.S., along with PRIME designation in Europe [14]. Safety and Tolerability - **Adverse Events**: The most common adverse events reported are mild to moderate injection site reactions. Anaphylaxis has occurred in seven patients, all of whom responded well to treatment [21][22][30]. - **Long-term Tolerability**: The drug has been generally well tolerated, with no patients dropping out due to injection site reactions. Education and pre-treatment with antihistamines are being implemented to mitigate risks [24][25][31]. Future Plans - **Phase 3 Trials**: Larimar is initiating a confirmatory phase 3 trial targeting ambulatory patients aged 2 to 40, with a focus on younger patients who progress more quickly [32][41]. - **Regulatory Engagement**: Ongoing discussions with the FDA are aimed at ensuring smooth regulatory submissions and trial initiation [36][41]. Additional Insights - **Patient Impact**: The disease significantly affects patients' daily lives, leading to loss of mobility and communication abilities. Larimar emphasizes the importance of addressing these challenges through their therapy [37][38][39]. - **Market Research**: Clinicians recognize the need for therapies targeting the root cause of FA, indicating a supportive environment for Larimar's approach [11][12]. This summary encapsulates the key points from the conference call, highlighting Larimar Therapeutics' commitment to addressing the unmet needs in the treatment of Friedreich's ataxia through innovative therapeutic approaches and regulatory strategies.

Financial Data and Key Metrics Changes - The company ended Q3 2025 with $328.6 million in cash, cash equivalents, and marketable securities, and raised an additional $48.7 million post-quarter through an ATM [20][21] - Total revenue for the quarter was $10.6 million, up from $4.9 million in Q3 2024, primarily due to a $6.7 million increase from collaboration with Biogen [20][21] - Net loss for Q3 was $38.3 million, or $0.65 per share, compared to a net loss of $26.4 million, or $0.47 per share, in the prior year, driven by increased operating expenses [20][21] Business Line Data and Key Metrics Changes - The company has made significant progress in the clinical development of zorevunersen, with over 200 patients identified for the phase 3 study, an increase from 150 previously reported [5][18] - R&D expenses rose to $37.7 million from $22.2 million a year ago, reflecting spending on the phase 3 study and early-stage pipeline advancements [20][21] - SG&A expenses increased to $16 million from $12.7 million, indicating investment in commercial capabilities [20][21] Market Data and Key Metrics Changes - The company is preparing for a meeting with the FDA to discuss expedited regulatory pathways for zorevunersen, which has received breakthrough therapy designation [6][19] - The market opportunity for zorevunersen is growing due to increased awareness of Dravet syndrome and the potential disease-modifying effects of the drug [6][19] Company Strategy and Development Direction - The company aims to rapidly scale its business to reach as many patients as possible with zorevunersen, focusing on medical affairs and commercial leadership [7][8] - There is a strategic emphasis on developing additional disease-modifying medicines, particularly in haploinsufficient disease areas [8][9] - The company is also launching a disease awareness campaign to improve diagnosis rates of Dravet syndrome through genetic testing [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory and the potential impact of zorevunersen on patients with Dravet syndrome [3][22] - The company is committed to educating the medical community and increasing awareness of Dravet syndrome [22] - Management highlighted the importance of the upcoming FDA meeting and the potential for expedited pathways to bring zorevunersen to market [19][22] Other Important Information - The company is actively recruiting for the phase 3 Emperor study, with 30 sites in the U.S., U.K., and Japan [17][18] - The first patient was randomized in August, and over 20 patients have been randomized so far [18] - The company anticipates completing enrollment in the second half of 2026, with data expected in late 2027 [39] Q&A Session Summary Question: What potential scenarios might be anticipated based on the PDD meeting with the FDA? - The company is preparing to present extensive data, including four-year safety data, to the FDA, which could lead to expedited pathways or a request to continue with the phase 3 study [26][27] Question: How clinically meaningful are the cognitive and behavioral improvements on the VABS-III data? - A change of one to three points on the VABS-III scale is considered clinically meaningful, with significant improvements observed in communication skills [31][33] Question: Can the company pursue early approval based solely on seizure reduction? - Yes, the company could seek approval based on seizure reduction, but it intends to pursue a label that reflects the disease-modifying potential of zorevunersen [37] Question: What are the common reasons for screen failure in the Emperor study? - Common reasons include not meeting the minimum seizure count required for enrollment, illness during the screening period, or family commitments [78] Question: How does the company plan to handle the differences in dosing schedules between phase 1/2 and phase 3 studies? - The company acknowledges the differences but believes the data from phase 1/2 and the open-label extension supports the dosing regimen planned for phase 3 [66]

Summary of Stoke Therapeutics Conference Call Company Overview - **Company**: Stoke Therapeutics - **Focus**: Development of treatments for Dravet syndrome, a genetic condition affecting neurodevelopment and seizures [1][2][3] Key Points Leadership Transition - Ian Smith has taken on the role of Interim CEO, having been with the company for approximately two and a half years [2][3] - Smith's background includes significant experience in biotech, particularly with Vertex Pharmaceuticals, where he worked on cystic fibrosis treatments [3] Disease Focus: Dravet Syndrome - Dravet syndrome affects approximately 40,000 individuals across major global regions, with an incidence of about 1 in 15,000 to 16,000 births [6][7] - The disease is characterized by severe seizures and significant neurodevelopmental delays, with many children not developing beyond the cognitive level of a two-year-old [8][9] Treatment Landscape - Current treatments primarily focus on seizure management, with no existing therapies addressing neurodevelopmental aspects [10][12] - Stoke's drug, zorevunersen, aims to modify the disease by restoring functional protein levels in the brain, potentially improving both seizure control and neurodevelopment [10][12] Clinical Data and Efficacy - In clinical studies, zorevunersen has shown a median seizure reduction of 85% when administered at a 70 mg dose, on top of existing anti-seizure medications [13][14] - The drug has demonstrated durability in seizure reduction over a four-year follow-up period, which is critical given the high mortality rate (20%) associated with Dravet syndrome [15][17] - Improvements in neurodevelopmental outcomes have been observed, with patients scoring significantly higher on the Vineland-3 scale compared to baseline [29][31] Phase 3 Study: AMPRO - The AMPRO study is a 52-week trial designed to evaluate the efficacy of zorevunersen, with a primary endpoint focused on seizure reduction [36][37] - The study aims to enroll 170 patients and is currently progressing well, with over 150 patients already in pre-screening [37] Regulatory Considerations - Stoke Therapeutics has received breakthrough therapy designation from the FDA, which may facilitate a faster path to market [39][41] - A meeting with the FDA is anticipated to discuss expedited filing options based on the existing safety and efficacy data [41] Market Potential and Value Proposition - The potential for zorevunersen to be a high-value treatment is emphasized, particularly if it can demonstrate significant improvements in both seizure control and neurodevelopmental outcomes [44][45] - The company aims to position zorevunersen similarly to other high-impact therapies in the market, such as those for cystic fibrosis [45] Future Outlook - The company is focused on advancing the AMPRO study and hopes to bring the treatment closer to patients, with aspirations for regulatory filing in the near future [48] Additional Insights - The emotional and developmental impact of Dravet syndrome on patients and families is highlighted, underscoring the importance of effective treatment options [9][10] - The potential for zorevunersen to change the trajectory of neurodevelopment in affected children is a key motivating factor for the company's mission [35][48]